title: Respiratory syncytial virus: disease, development and treatment.
abstract: Respiratory syncytial virus (RSV) is spread by droplets and causes infections of the upper and lower respiratory tract. It is most common in infants, children under the age of five years and the elderly. Due to the nature of the transmission, infections with RSV are contagious but usually short lived. Pharmacological treatment involves the use of antiviral medication. Nurses caring for older people, infants or young children should be aware of the risk of transmission of RSV, pathogenesis and treatment options available to effectively manage the care of patients.
authors.affiliation: Brunel University, School of Health Sciences and Social Care, Middlesex.
authors.forename: Maggi
authors.initials: M
authors.lastname: Banning
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D006801:Humans; D007223:Infant; D024802:Nurse's Role; D010102:Oxygen Inhalation Therapy; D000069455:Palivizumab; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D018357:Respiratory Syncytial Virus Infections / Q000175:diagnosis / Q000628:therapy / Q000635:transmission; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000628:therapy / Q000635:transmission; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; C483969:CFY196; D011993:Recombinant Fusion Proteins; D012254:Ribavirin; D000069455:Palivizumab